title: Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?
authors.forename: P C M
authors.initials: PC
authors.lastname: van de Kerkhof
authors.forename: U
authors.initials: U
authors.lastname: Mrowietz
authors.forename: S
authors.initials: S
authors.lastname: Segaert
authors.forename: K
authors.initials: K
authors.lastname: Kragballe
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000031:analogs & derivatives / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004333:Drug Administration Routes; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D012871:Skin Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D001688:Biological Products; D003879:Dermatologic Agents; C055085:calcipotriene; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D002117:Calcitriol